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Cardiac resynchronization therapy (CRT) is an established non-pharmacological treatment for selected heart failure patients with wide
QRS duration. However, there is a persistent number of non-responders throughout. The prediction of the CRT response is paramount
to adequately select the correct patients for CRT. One of the expanding fields of research is the development of biomarkers that predict
the response to CRT. A review of the available literature on biomarkers in CRT patients has been performed to formulate a critical ap-
praisal of the available data. The main conclusion of our review is that biomarker research in this patient population is very fragmented
and broad. This results in the use of non-uniform endpoints to define the CRT response, which precludes an in-depth comparison of the
available data. To improve research development in this field, a uniform definition of the CRT response and relevant endpoints is neces-
sary to better predict the CRT response.
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Introduction
Cardiac resynchronization therapy (CRT) is an extensively validated
treatment for symptomatic heart failure (HF) patients with reduced
left ventricular ejection fraction (LVEF), prolonged QRS duration,
and abnormal QRS morphology. Following the most recent
European Society of Cardiology (ESC) guidelines,1 there is strong evi-
dence for CRT implantation in HF patients [New York Heart
Association (NYHA Class II–IV)] with a LVEF below 35%, and with a
QRS duration of more than 150 ms with left bundle branch (LBB)
block morphology. For other subgroups of patients, CRT might still
be useful although evidence is less compelling.1 However, despite a
moderate improvement over the last two decades, the response to
CRT is still rather mixed. The recent Clinical Trial of the SonRtip lead
and automatic AV-VV optimization (RESPOND-CRT) trial2 showed
a clinical composite response rate of 77% in CRT patients with LBB
block and only 66% in CRT patients without LBB block.
Furthermore, the proportion of so-called ‘super-responders’ to CRT
defined by almost complete normalization of ventricular function and
volumes) has remained constant over time, still representing not
more than 30% of all CRT patients. The timely prediction of a CRT
response, especially a super-response, is therefore of paramount im-
portance. Although numerous other factors do determine the
success of CRT (e.g. optimization of the device, lead positioning,
etc.), early identification, or even prediction, of CRT response might
have long-term beneficial therapeutic consequences.
Numerous attempts have already been made to find a reliable bio-
marker(s) to predict the response to CRT. A good, clinically useful
biomarker has to be specific for the condition that needs to be
detected, yet at the same time display adequate sensitivity for the
pathologic condition. Ideally, it has strong predictive value, is robust
and reproducible over time. Preferentially, the biomarker can be
assessed non-invasively, is readily accessible (e.g. a simple blood test)
and its use should be supported by both pre-clinical and clinical data.
In this review article, we aimed to present a summary of the stud-
ies on biomarkers that have been performed so far, highlighting the
fact that more focused research is mandatory to find a reliable bio-
marker (panel) to predict the CRT response.
Methodology and search strategy
PubMed.gov as a research literature platform (http://ncbi.nlm.nih.
gov), and Medical Subject Headings (MeSH) were used to identify rel-
evant publications irrespective of the publication date. The following
MeSH terms were combined as follows: ‘biomarkers’ [MeSH] OR
‘microRNA’ [MeSH] OR ‘protein’ [MeSH] OR ‘genes’ [MeSH] AND
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‘cardiac resynchronization therapy’ [MeSH] OR ‘cardiac resynchroni-
zation therapy devices’ [MeSH]. This research retrieved 231 papers
that were screened for eligibility. Based on careful review of the ab-
stract, 181 records were excluded. The remaining 50 papers were
assessed for eligibility based on full-text review. A total number of
8 papers were excluded, because of the following reasons: 4 were
reviews, 1 paper only described a study protocol and no data, and 3
manuscripts were basic research papers (no patient data), irrelevant
for this review. Finally, the remaining 42 papers were included in the
qualitative analysis of this review. The search was conducted in
November 2017 and updated in June 2018.
Cardiac biomarkers in
resynchronization therapy
Brain-derived natriuretic peptide (BNP) and its amino-terminal linked
counterpart (NT-pro-BNP) are widely accepted diagnostic and prog-
nostic markers in HF patients.1 Therefore, their potential to predict a
response to resynchronization therapy has been investigated. In
2013, Brenyo et al. investigated the predictive value of BNP in a sub-
group of the landmark Multicenter Automatic Defibrillator
Implantation with Cardiac Resynchronization Therapy (MADIT-
CRT) trial study, with mildly symptomatic HF.3,4 Both baseline and 1
year of follow-up BNP levels were assessed in 1197 patients. As
expected, elevated baseline BNP was associated with a 68% in-
creased risk of HF or death (P=0.007) in patients allocated to CRT-
D as well as in those receiving implantable cardioverter-defibrillator
(ICD)—in the ICD-only group, the increased risk of HF or death was
58% (P=0.02). Importantly however, at 1 year of follow-up, patients
who received CRT showed significantly greater reductions in BNP
levels (26%) compared to ICD-only patients (8% increase, P=0.005
for the difference). Moreover, in the CRT-D group, lower 1-year
BNP levels were associated with a significantly lower risk of HF or
death, compared to the subgroup where BNP levels remained high.
Furthermore, the echocardiographic response to CRT-D was the
highest in patients maintaining or attaining low BNP levels at 1 year of
follow-up.3 In the same patient group, elevated baseline and
follow-up BNP levels were independent predictors of increased risk
for ventricular tachyarrhythmias [ventricular tachycardia/ventricular
fibrillation (VT/VF)], whereas reduced BNP levels following CRT-D
implantation coincided with a lower incidence of VT/VF during fol-
low-up.5 Further evidence for the usefulness of BNP as a predictor of
the CRT response was obtained in a prospective follow-up study of
267 HF patients with an average LVEF of 25% ± 8% (meanþ SD) un-
dergoing CRT-D implantation.6 Both individually and in combination,
baseline high-sensitivity troponin T (hsTnT) and BNP values—in a
multivariate Cox regression model including age, NYHA class, LVEF,
and QRS duration—were independent predictors of outcome, de-
fined as death or HF hospitalization. A risk category based on the ele-
vation of two, only one, or none of the investigated biomarkers,
proved a significant predictor of outcome, with respective hazard ra-
tios (HRs) of 7.34 [95% confidence interval (CI) 2.48–21.69] and 2.50
(95% CI 1.04–6.04) for high- and intermediate risk groups. Also, in a
smaller study in which 105 HF patients (68% men, aged 65.4 ±
10.1 years) were followed for BNP levels and inflammatory markers,
lower BNP levels were observed in both the objective responders to
CRT [defined as a reduction of >_15% in left ventricular end-systolic
volume (LVESV)] and in the subjective response to CRT (defined as
an improvement of >_10 points on the patient-reported Kansas City
Cardiomyopathy Questionnaire).7 Altogether, these studies provide
convincing evidence for the use of BNP as a predictor of the re-
sponse to CRT.
Soluble suppressor of tumorigenicity 2 (sST2) is a protein that is
encoded by the IL1R1 gene (interleukin 1 receptor 1) and it basically
reflects adverse cardiac remodelling and fibrosis. Its interesting role
as a biomarker in HF has been described elsewhere,8 but its involve-
ment in the CRT response predictionwas also assessed in a subpopu-
lation of the MADIT-CRT trial (n=410, NYHA Class I/II). In
multivariate-adjusted models, elevated baseline sST2 was associated
with an increased risk of death, death or HF, and death or ventricular
arrhythmia, even when adjusting for baseline BNP levels.9
Furthermore, lower baseline sST2 levels coincided with a greater risk
reduction with CRT-D (P=0.006). This was confirmed uponmeasur-
ing sST2 serially over time. Unfortunately, no data are available about
serial measurements of sST2 after CRT and how baseline sST2 levels
predict the response to CRT.
Galectin-3, also a marker of fibrosis, is a soluble beta-galactoside-
binding lectin that has a regulatory function in fibrosis, tissue repair,
and inflammation.10Again, this biomarker was tested in a subgroup of
the MADIT-CRT population (n=654, NYHA I/II)11with non-fatal HF
events or death as study endpoints. Patients having a baseline
galectin-3 level in the upper quartile of the distribution, also had a
65% reduction in the occurrence of the primary endpoint if given
CRT-D (HR 0.35, 95% CI 0.19–0.67). In contrast, patients having
lower galectin-3 levels at baseline only had a 25% non-significant risk
reduction (HR 0.75, 95% CI 0.51–1.11), meaning that the patients
with the highest risk for HF had the greatest benefit of CRT implanta-
tion. Baseline galectin-3 level was an independent predictor of out-
come (HR 1.55, 95% CI 1.01–2.38; P=0.043).11 Similar results were
obtained in a subpopulation of the CARE-HF trial,12 showing
galectin-3 as an independent predictor of worse overall cardiovascu-
lar outcome, however not predicting the response to CRT as a sepa-
rate outcome parameter.13 Although caution needs to be taken
when interpreting all these results together, it seems that sST2 and
galectin-3, markers of fibrosis and to some extent ventricular remod-
elling, better reflect the ongoing processes during successful resynch-
ronization therapy, compared to NT-pro-BNP, BNP, or troponin.
However, a head-to-head comparison in a prospective follow-up
study would be helpful to determine the most specific cardiac bio-
marker related to the CRT response.
The abovementioned biomarkers (NT-pro-BNP, hsTnT, galectin-
3, and sST-2) were also tested for their predictive value in estimating
the improvement of mitral regurgitation (MR) after implanting a CRT
device in 132 patients. From the BIOCRT study,14 it appeared that
higher galectin-3 levels at the time of CRT implantation conveyed a
MR non-improvement (status quo or worsening) after 6months.
Although these patients also had higher hsTnT at baseline, after mul-
tivariate analysis only galectin-3 prevailed as a statistically significant
predictor of MR evolution. Conversely, in the patients who had an
improvement in MR, absolute levels of NT-pro-BNP and sST2 were
lower at follow-up however without reaching statistical
significance.14
















































































































Heart failure patients display elevated inflammatory markers which
correlate with morbidity and mortality.15 In one study,16 the predic-
tive power of the most frequently used inflammatory marker, high-
sensitivity C-reactive protein (hsCRP) was investigated in 65 HF
patients eligible for CRT (46 males, mean age 65 ± 12 years, NYHA
III/IV). Levels of both hsCRP and BNP were measured before device
implantation. Reverse remodelling, an element of beneficial response
to CRT, was defined as >15% reduction in LVESV. In this patient co-
hort, the hsCRP levels were significantly higher in the non-
responders than in the responders (P<0.01). Moreover, multivariate
logistic regression analysis showed a relationship between hsCRP
Presumed pathophysiological mechanisms underpinning




















































Figure 1 Central figure illustrating the presumed pathophysiologic pathways involved in left ventricular reverse remodelling, and hence the re-
sponse to cardiac resynchronization therapy. BNP, brain natriuretic peptide; CRT, cardiac resynchronization therapy; CT, carboxyterminal; hs, high-
sensitive; LV, left ventricle; miR, microRNA; N/L, neutrophil/lymphocyte; NT, amino-terminal; RV, right ventricle; ST, soluble factor of tumorigenicity;
TIMP, tissue inhibitor of metalloproteinase.



























































































































3 Brenyo 2013 1197 BNP Echocardiographic: reduc-
tion in LVESV as a con-
tinuous variable
12 • Elevated baseline BNP was associated with
68% (P = 0.007) (CRT-D) and 58% (P = 0.02)
(ICD) increase in risk of HF or death
• If BNP was low, or reduced, after implanta-
tion, CRT response was significantly better
Prognostic but not predictive for
response





12 • Division in three groups: high TnT þ high
BNP, low TnT þ low BNP, or a combination
of one high- and one low-level biomarker
• Significant difference in event-free survival:
the higher the levels of the biomarkers, the
worse the survival (log-rank P < 0.001)
Prognostic but not predictive for
response
7 Brouwers 2014 105 BNP
Inflammatory
markers
>15% decrease in LVESV 14 • Subjective responders had lower TNF-alpha
levels at baseline, but no difference in BNP
• Objective response was associated with
lower BNP over time
• Subjective response was associated with
lower TNF-alpha levels
Strongest association between sub-
jective response to CRT, not ob-
jective response
16 Kamioka 2012 65 hsCRP >15% decrease in LVESV 6 Multivariate logistic regression analysis showed
an independent relationship between hsCRP
and the incidence of non-responders (OR
1.499, P = 0.011)
Limited patient number





3 CRP levels significantly decreased following suc-
cessful resynchronization
Very limited patient number
18 Szlepaki 2016 126 Complement C3a
NT-pro-BNP
Not defined 6 CRT reduced C3a (P < 0.0001), sC5b-9 (P =
0.0006) but not total C3 levels; and C3a pre-
dicted 5 years of mortality of patients inde-
pendent of NT-pro-BNP
Effect on mortality, not on CRT
response
20 Boros 2016 122 Neutrophil/lym-
phocyte ratio
>15% decrease in LVESV 6 A baseline NL ratio exceeding 2.95 predicted
lack of remodelling and 2 years of mortality,
independent of NT-pro-BNP
–
21 Belperio 2016 257 Inflammatory
mediators
>15% decrease in LVESV 12 Baseline detectable IL-13 was significantly associ-
ated with the CRT response, while baseline










































6 In non-responders, TGF-beta1 levels significantly
increased, and baseline TGF-beta1 level was a
significant predictor of poor prognosis
–
23 Limongelli 2014 44 Cardiotrophin-1 >15% decrease in LVESV 6.4 ± 0.79 Multivariate logistic model showed CT-1 as an
independent predictor of CRT echo response
(OR 0.97, P = 0.005)
Very limited patient number
25 McAloon 2017 260 ECM biomarkers n/a: meta-analysis n/a Lower type I and type III collagen synthesis bio-
markers (N-terminal propeptides of type I and
III procollagens) predict reverse left ventricu-
lar remodelling
Meta-analysis of very different study
populations
26 Dong 2011 45 Neurohormonal
markers
>15% decrease in LVESV 6 Baseline PIIINP, and not the other biomarkers,
was lower in CRT responders than in non-
responders (P = 0.03); a less elevated PIIINP
level in HF might be an independent bio-
marker predicting better response to CRT
(OR 0.2, P = 0.07)
Very limited patient number
27 Trucco 2016 42 pTIMP1 ‘Clinical response, LV
remodelling and
mortality’
6 Baseline TIMP-1 levels are powerful predictor of
long-term mortality in CRT-treated HF
patients
Very limited patient number, associ-
ation with mortality but not CRT
response
29 Francia 2011 12 Osteopontin Echocardiographic deter-
minants of response to
CRT
8.5 ± 4 Reverse remodelling due to CRT is reflected by
changes in osteopontin
Very limited patient number, no pre-
dictive value
31 Michelucci 2016 73 Antibodies against
beta1 adrener-
gic receptors
>15% decrease in LVESV 6 Retrospective analysis showed a higher percentage
of Patients positive for beta1-autoantibodies
(57% vs. 27%, P = 0.004)
limited patient number
36 Schmitz 2014 207 Genetic markers >15% decrease in LVESV 6 Four genetic variants were associated with the
CRT responder phenotype at the allelic and
genotypic level
No predictive value
37 Marfella 2013 81 Circulating
microRNAs
LV remodelling 12 Reverse remodelling is associated with favour-
able changes in miRNAs that regulate cardiac
fibrosis, apoptosis and hypertrophy
Limited patient number, no predic-
tive value
38 Melman 2015 12 (test) þ
61 (val.)
MicroRNA-30d >10% increase in LVEF 6 Baseline plasma miR-30d levels are associated
with response to CRT
Very limited patient number





6 Plasma concentrations of MDA, CAT, SOD and
GPX were reduced in CRT responders
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and the incidence of a non-response [odds ratio (OR) 1.499,
P=0.011]. In addition, the strongest predictive factor for cardiac
death was an elevated hsCRP (HR 1.337, P=0.001), with a cut-off of
3mg/L.16 In another small pilot study (36 CRT patients) where special
focus was attributed to extracellular matrix elements, CRP decreased
following successful resynchronization therapy.17
Complement C3A
Another intriguing parameter is the amount of activated complement
C3 (C3a) as a marker of chronic inflammatory state. One study inves-
tigated prospectively several components of the complement cas-
cade (total C3, C3a, sC5b-9) in 126 HF patients, at baseline and
6months after CRT implantation. Strikingly, CRT reduced the C3a
levels (and sC5b-9 levels), and measuring C3A allowed to predict 5
years of mortality of the patients (C3a level >165ng/mL aligned with
an HR of 4.21, 95% CI 1.65–10.72, P=0.003), and this effect appeared
to be independent of the NT-pro-BNP levels that were measured
simultaneously.18
Blood cell-derived parameters
Since a low lymphocytic count and high neutrophil count in haemo-
grams of patients with HF are associated with a dismal prognosis in
chronic HF, these parameters have been investigated in the CRT
population. One of the main explanations for these higher neutrophil
counts are an increased activation of the innate immune system in
HF, and an increased neutrophil life span (viability) in HF patients.19 In
a large observational study by Boros et al.,20 qualitative blood counts
and NT-pro-BNP were analysed, with 2 years of mortality as primary
endpoint and reverse remodelling at 6months (>15% decrease in
LVESV) as secondary endpoint. A neutrophil/lymphocyte ratio over
2.95 predicted the absence of reverse remodelling (OR 0.38 with
95% CI 0.17–0.85) and 2 years of mortality, independently of NT-
pro-BNP.20 Another, retrospective, analysis demonstrated the same
finding, namely that baseline neutrophil/lymphocyte ratio was signifi-
cantly higher in non-responders. In this study, patients having a ratio
>3.45 had a 12-fold increased risk of CRT non-response.20 The latter
study also investigated platelet to lymphocyte ratio and percentage
of lymphocytes, but these values had less predictive value.
Other inflammatory markers
Markers that sit on horseback of both inflammation, fibrosis, and
remodelling are of considerable interest because they grasp impor-
tant parts of the pathophysiological alterations in HF. Therefore, in-
terleukin (IL)-6, IL-1a, IL-1b, IL-4 and IL-13, epidermal growth factor,
and fibroblast growth factor 2 (FGF-2) were investigated in the multi-
centre Inflammatory Mediators and Clinical Outcome in Patients
with Advanced Heart Failure Receiving CRT (RISK) study.21 On mul-
tivariate analysis of 257 patients, two markers were particularly regu-
lated. Interleukin-13 was significantly associated with the primary
outcome, a combination of freedom of HF hospitalizations, death,
and decrease in LVESV of >15% at 12 months’ of follow-up.
Detectable vs. non-detectable IL-13 levels were associated with an
OR of 3.79 (95% CI 2.10–6.82, P=0.0001). Conversely, detectable
FGF-2 levels were negatively associated with the primary endpoint
(OR 0.31, 95% CI 0.14–0.68; P=0.004).21 In the Brouwers study7 de-
scribed earlier, only lower tumour necrosis factor (TNF)-a levels











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2 Overview of the biomarkers and their mechanism of action discussed in this review







Markers of increased cardiac wall stress, functions as a hormone
inducing natriuresis, diuresis, vasorelaxation, inhibition, or the
RAAS system
Sacubitril interferes with BNP
metabolism
High-sensitivity troponin T hsTnT Part of the troponin complex, located in the thin filament of
cardiac muscle cells, regulating muscle contraction in intracel-
lular calcium ion transportation
–
Soluble suppressor of tumorige-
nicity 2
sST2 functions as a ‘decoy’ receptor for interleukin 33, inhibiting IL-
33/ST2 signalling
–
Galectin-3 Gal-3 Plays a role in numerous cellular functions including apoptosis,




hsCRP Belongs to the pentaxin family and is involved in several host
defense related functions
–
Complement C3a C3a Modulated inflammation as a proteolytically processed alpha
subunit
Possesses antimicrobial activity
Neutrophil/lymphocyte ratio – – –
Interleukin-13 IL-13 Immunoregulatory cytokine produced by activated Th2 cells, in-
volved in B-cell maturation and differentiation
Critical for the pathogenesis of
allergen-induced asthma
Fibroblast growth factor 2 FGF-2 Cytokine having broad mitogenic and angiogenic activity, impli-
cated in limb and nervous system development, wound heal-
ing and tumour growth
–
Interleukin-6 IL-6 Cytokine having an important function in inflammation and mat-
uration of B cells, capable of inducing fever in autoimmune
disease or infection
Anti-IL-6 agents are antirheu-
matic agents
Tumour necrosis factor alpha TNF-alpha Proinflammatory cytokine secreted by macrophages Anti-TNF agents are anti-inflam-
matory agents
Cardiotrophin 1 CT-1 Cytokine inducing cardiac myocyte hypertrophy in vitro –
N-terminal propeptides of




type I collagen telopeptide PICP Carboxyterminal collagen crosslink, a byproduct of collagen
synthesis
–
Matrix metalloproteinase 1 MMP-1 Enzyme involved in the breakdown of the extracellular matrix
(breakdown of collagen)
–
Tissue inhibitor of matrix metal-
loproteinase 1
TIMP-1 Natural inhibitor of matrix metalloproteinases –
Transforming growth factor
beta1
TGF-beta1 Secreted ligand of TGF-beta1 superfamily, binding to TGF-beta
receptors, finally regulating cell proliferation, differentiation
and growth
–
Osteopontin – Involved in the attachment of osteoclasts to the mineralized
bone matrix
–
Intermedin – Member of the calcitonin gene-related peptide family of hor-
mones that play a role in the regulation of cardiovascular ho-
meostasis, prolactin release, anti-diuresis, anti-natriuresis and




– Adrenergic receptors are a prototypic family of guanine nucleo-
tide binding regulatory protein-coupled receptors that medi-
ate the physiological effects of epinephrine and
norepinephrine
Therapeutic target of beta-
blocking agents
MicroRNA-30 cluster miR-30d – –
Annexin A5 – Phospholipase A2 and protein kinase C inhibitory protein with
calcium channel activity and a potential role in cellular signal
transduction, inflammation, growth and differentiation
–
Continued














































































































objective response), in contrast to any other investigated marker
[CRP, IL-6, soluble tumor necrosis factor receptor (sTNFr)1, and
sTNFr2]. In a smaller study involving 46 CRT responders and 35 non-
responders without any relevant baseline differences, concentrations
of IL-6 and TNF-a significantly decreased in the responders to
CRT.22 And finally, levels of cardiotrophin-1 (CT-1), a member of the
IL-6 family, significantly decreased in 15 CRT non-responders vs. 29
responders in a pilot study.23 In a multivariate analysis, baseline CT-1
appeared as an independent predictor of CRT response, at least fol-
lowing echocardiographic standards (>15% decrease of LVESV) (OR
2.7, 95% CI 1.4–4.3; P=0.01).23
The extracellular matrix
One of the most important features of a beneficial CRT response, es-
pecially in the super-responders to CRT, is impactful reverse remod-
elling of the left ventricle. This process involves significant
improvement of contractile function, thickening of the walls to again-
physiological properties, and a decrease of the LVESV.24A systematic
review on extracellular matrix biomarkers has been published re-
cently.25 N-terminal propeptides of type I and type III procollagens
(PINP and PIIINP), type I collagen telopeptide (ICTP), and matrix
metalloproteinase 1 (MMP-1) were measured in a subpopulation of
the CARE-HF trial patient group (260 patients). In a multivariate
model, these markers did not predict a CRT response, although
some of them were associated with long-term cardiovascular out-
comes.13,26 Similar findings were obtained for MMP-1 and tissue in-
hibitor of metalloproteinase 1 (TIMP-I) in a pilot study involving 42
patients.27 In another small pilot study (n=27 ischaemic cardiomyop-
athy patients of which only 15 receiving CRT), MMP-9, TIMP-1, ICTP,
and carboxyterminal propeptide of type 1 procollagen (PICP) were
determined before and 12weeks after CRT implantation.28 With re-
spect to cardiac function parameters, the MMP-9/TIMP-1 ratio corre-
lated positively with LVEF, but the meaning of these findings is still
unclear as the patient groups are very small. In the Osmancik paper,22
discussed earlier, tissue growth factor (TGF)-b1—a stimulator of fi-
brosis development—significantly decreased in CRT responders,
whereas in non-responders, TGF-b1 significantly increased. In this
study, TGF-b1 was a significant predictor of death during follow-up.
Also osteopontin, a matrix glycoprotein required for the activation
of fibroblasts upon TGF-b1 stimulation, is altered in patients who
show signs of CRT-induced reverse remodelling: plasma osteopontin,
higher in HF patients compared to healthy controls, decreased in
CRT responders, and even increased in non-responders (pilot trial
involving only 12 CRT patients).29
Adrenergic signalling
Intermedin (adrenomedullin-2) is a member of the calcitonin gene-
related peptide (CGRP) family of hormones, which play a role in the
regulation of cardiovascular homeostasis, anti-diuresis, anti-natriure-
sis, and prolactin release.30 Strikingly, also auto-antibodies for b1-
adrenergic and muscarinic receptors are found in HF patients
throughout. In a retrospective analysis of 73 HF patients31 (NYHA II–
III–IV, LVEF <35%), who all received CRT-D therapy, those auto-
antibodies were measured in CRT responders and non-responders.
A significantly higher percentage of patients with b1-positivity was
observed in the non-responders (57% vs. 27%; P=0.004), whereas
antimuscarinic antibodies were not differentially regulated. The adre-
nergic signalling cascade is of great importance in HF: the
blunted myocardial contractile reserve is partially caused by a down-
regulation of b1-adrenoreceptors in the myocardium. In a
preliminary study involving a limited number of patients, the proof-
of-concept was shown that successful CRT pacing resulted in a signifi-
cant up-regulation of b1-adrenoreceptor gene expression in the
myocardium.32 Pezzali et al. showed that gene polymorphisms in
beta-adrenergic receptors may influence the LV reverse remodelling
after CRT, and possibly also the incidence of malignant ventricular
tachyarrhythmias.33
Molecular alterations in cardiac
resynchronization therapy
responders
In 2008, an important paper was published describing for the first
time in detail some of the genetic alterations that occur in CRT res-
ponders.34 Twenty-four patients underwent left ventricular biopsy
procurement prior to CRT implantation, and 17 of them underwent
biopsy procurement 4months after implantation. Molecular markers
at these time points were compared to a small control group of
patients with normal cardiac function undergoing coronary artery by-
pass grafting. Responders to CRT were defined as having an increase
in NYHA Class of >1, and a relative increase in LVEF of >_25% at
4months. Compared to the control group, HF patients had lower LV
mRNA levels of alpha-myosin heavy chain (a-MHC), b-MCH, sarco-
plasmic reticulum calcium ATPase 2-alpha (SERCA2a), phospholam-
ban (PLN), and significantly higher BNP mRNA levels. The CRT
responders had an increase in a-MHC, SERCA2a, an increased a-/b-
MCH ratio, an increased SERCA2a/PLN ratio, and significantly lower
BNP levels, while no significant changes in molecular profile were
....................................................................................................................................................................................................................
Table 2 Continued
Biomarker Abbreviation Mechanism of action Therapeutic role of the
biomarker
CT-apelin – Endogenous ligand for the G-protein-coupled apelin receptor,
regulating fluid homeostasis, cardiovascular function, and in-
sulin secretion
–
Cystatin C CysC Extracellular inhibitor of cysteine proteases –














































































































observed in non-responders. The results shed light on the genetic
mechanisms inducing reverse remodelling, which is the underlying
process resulting in a beneficial response to CRT.35 However, these
molecular markers cannot serve as useful biomarkers because pro-
curement of LV biopsies is too invasive for this purpose.
In a large consecutive follow-up study, correlation between a CRT
response and genetic variants at an allelic and genotypic level was
performed.36 A total of 207 patients out of 1421 were selected and
divided between responders and non-responders, and were subse-
quently matched for their baseline parameters before CRT. A CRT
response was defined as a decrease in LVESV of >15% at follow-up
echocardiography compared to baseline. Genomic DNA, extracted
from patient’s blood during follow-up visit, was used to perform gen-
otyping of a selection of genetic variants based on extensive literature
search focusing on cardiovascular disease and vascular remodelling.
Four genetic variants—both at allelic and genotypic level—were
identified with CRT response, in the following genes: ATPIB1, guanine
nucleotide-binding beta polypeptide 3 (GNB3), nuclear receptor
subfamily 3 group Cmember 2 (NR3C2), and tumour necrosis factor
superfamily member 11 (TNFSF11).36 The further-reaching aspects
of this study are however that machine learning algorithms were
used to fine tune the prediction of a (non-)response, based on a com-
bination of clinical parameters and the above-mentioned genetic
variants.
Epigenetic alterations in cardiac
resynchronization therapy
In the last decennium, the number of publications on epigenetic regu-
lation in the cardiovascular field has boomed. In particular
microRNAs play various roles in controlling processes of cardiac hy-
pertrophy, fibrosis, angiogenesis, apoptosis, among others. Sardu and
co-workers investigated whether LV reserve remodelling after CRT
was associated with changes of circulating microRNAs in patients
with dyssynchronous HF.37 In this prospective, non-randomized trial,
84 microRNAs levels were determined in 81 patients with HF eligible
for CRT, against 15 healthy controls and 60matched non-HF patients
but with concomitant diseases. In the CRT population, 55 patients
displayed a beneficial response, whereas the remaining 26 patients
were non-responders at 12months. At this follow-up period, the res-
ponders displayed a differential expression pattern than the
non-responders: in the former group, microRNA-26b-5p, -145-5p, -
92a-3p, 30e-5p, and -29a-3p (P<0.01 for all microRNAs).
In 2015, the study of Melman38 investigated the potential of 766
plasma-derived microRNAs at baseline in 12 CRT patients, with and
without subsequent echocardiographic improvement at 6months af-
ter CRT. After this pilot phase, candidate microRNAs were validated
in 61 additional patients. Higher baseline microRNA-30d levels,
expressed in cardiomyocytes and released in vesicles in response to
mechanical stress, appeared to be associated with a beneficial CRT
response, here defined as a relative increase in LVEF >_15%. Although
these results seem promising, a large validation study of microRNA-
30d as a biomarker for CRT response is currently still lacking.
From these epigenetic data, it appears that the microRNA-30 clus-
ter, consisting of microRNA-30a, -30 b, -30c1, -30c2, -30d, and -30e
is critically involved in the remodelling of the left ventricle, potentially
by its important role in the extracellular matrix,39 angiogenesis,40 and
autophagy.41 Further large validation data are eagerly awaited to con-
firm or refute the role of microRNAs in predicting the response to
CRT.
Biomarkers related to oxidative
stress and apoptosis
Few papers have explored the diagnostic potential of oxidative
stress- or apoptosis-related molecules to predict a response to CRT.
In a study comprising 51 patients treated with CRT, serummalondial-
dehyde, catalase, superoxide dismutase, and glutathione peroxidase
were all reduced, and correlated with echocardiographic parameters
of systolic function.42 Ceruloplasmin, a metalloprotein that binds
copper and has ferroxidase activity, is a marker of oxidative stress
and is altered shortly after implantation of CRT, although the clinical
usefulness of this finding is still under investigation.43 On the other
hand, annexin A5, a protein related to cellular damage, was moni-
tored in 57 patients with HF that received CRT, at baseline and 1 year
of follow-up. No differences between annexin A5 levels at baseline
were observed between responders and non-responders, but after 1
year of successful CRT, annexin A5 significantly decreased, and
remained unchanged in non-responders.44
CT-apelin
Apelin is the endogenous ligand for a G-protein-coupled apelin re-
ceptor and is investigated as an important regulator of cardiovascular
homeostasis. There are several cleaved shorter peptides (apelin-36,
apelin-13, etc.) originating from the 77-amino acid preproapelin, and
these shorter peptides are grouped as carboxyterminal apelin frag-
ments (CT-apelin).45,46 In 81 patients with severe HF and implanta-
tion of a CRT device, CT-apelin was measured at baseline and 6
months after implantation. A total of 18.5% were non-responders,
whereas the rest were CRT responders. At baseline, there was no
difference in CT-apelin levels in both groups, but after 6 months, CT-
apelin was significantly lower in the responders (P<0.001).47 Based
on multivariate analysis, CT-apelin was judged superior to NT-pro-
BNP in association with responder status. However, both markers
cannot be considered predictors of CRT response as there were no
baseline differences.
Cystatin C
Cystatin C (CysC) is a protein encoded by the CST3 gene. All human
nucleated cells produce CysC as a chain of 120 amino acids which
functions as an intracellular inhibitor of lysosomal proteinases and an
extracellular inhibitor of cysteine proteases. The clinical relevance of
CysC stems from extensive research in kidney failure, where the
marker is of superior accuracy to more conventional, established
markers of renal dysfunction e.g. serum creatinine.48 Moreover,
CysC levels have been shown to coincide with worse clinical out-
come and the occurrence of clinically relevant events in patients with
HF.49 This observation lead to the hypothesis that CysC might be of














































































































interest to predict adverse, or beneficial, outcome in HF patients
whom receive resynchronization therapy. The first report on the rel-
evance of CysC levels in predicting outcome in CRT patients was
published in 2013.50 Yamamoto et al. showed that elevated CysC lev-
els were significantly associated with long-term outcome (mortality
and cardiovascular events) in 117 patients with a median follow-up
time of 3.2 years and an incidence rate of 29.1% for mortality, and
50.4% for cardiovascular events. This finding remained consistent
even after multivariate Cox regression analysis. However, there was
no superiority of CysC compared to the glomerular filtration rate
(eGFR) to predict the response to CRT.50 A few years later, in the
BIOCRT study,51CysC levels were measured in 133 patients, both in
peripheral venous and coronary sinus (CS) blood samples. Classical
serum creatinine levels and eGFR, were measured simultaneously.
The three markers (CysC, creatinine, and eGFR) were predictive of
major adverse cardiac events (MACEs) during a follow-up term of on
average 2 years, but only baseline CysC levels were associated with
the identification of adverse clinical outcome after CRT implantation.
CysC levels associated with CRT non-response at 6months with an
adjusted OR of 3.6 (P=0.02). Moreover, the addition of CysC to
classical predictive parameters resulted in an improved prediction of
CRT non-response (P<_ 0.003). On top of that, serial measurements
of CysC resulting in absolute values of >1mg/L were associated with
a CRT non-response and a reduced 6-min walk distance, as well as 2
years of MACE (P<_ 0.04).51 Of note, the measurement of CysC lev-
els in CS blood had no added value with respect to prognostic signifi-
cance, meaning that peripheral blood-derived CysC levels were
sufficient to predict adverse response to CRT, a feature improving
the usefulness of CysC as a biomarker. Overall, the importance of
CysC in the prediction of the response to CRT relates to the fact




In this review, we gave an overview of the currently available evi-
dence on biomarkers predicting the response to CRT. How should
we interpret the amount of evidence presented here? As far as the
classical HF biomarkers are concerned (NT-pro-BNP, BNP, hsTnT,
sST2, Gal-3), a beneficial response to CRT coincides with lower val-
ues of these molecules. This finding however does not mean that
these biomarkers can predict the CRT response before implantation!
Rather these molecules reflect a beneficial reverse remodelling pro-
cess after implantation. With respect to the biomarkers related to in-
flammation (hsCRP, complement C3a), it is interesting to note that
inflammation plays an important role in the remodelling process in
HF. Therefore, targeting the inflammatory pathway to find predictive
biomarkers for CRT, is reasonable. Of particular interest seems com-
plement C3a, because it also brings prognostic information on mor-
tality after CRT implantation, beyond NT-pro-BNP levels. Closely
linked to inflammation is the extracellular matrix, a paramount player
in the remodelling process. In general, sample sizes of the studies on
ECM-related biomarkers, adrenergic signalling, and others are too
small to make relevant conclusions. Interestingly, high CysC levels at
baseline coincided with adverse 6-month response to CRT, making it
a potentially interesting biomarker. However, until now, it is unclear
whether the predictive value of CysC is preserved when adjusting for
the grade of chronic kidney failure, and this should be investigated in
a large patient population.
It is clear that the need to better predict the response to CRT
reflects an important clinical question as many attempts to find a use-
ful biomarker have been undertaken. On the other hand, we conclude
from our literature search that not a single biomarker is currently able
to better predict the CRT response, on top of already known clinical
markers. First, we have to acknowledge that a lot of research is per-
formed, which is very positive. However, outcomes of the studies dis-
cussed are rather diffuse and difficult to interpret. This is due to the
fact that (i) different definitions are applied to define the CRT re-
sponse, (ii) it is sometimes unclear whether a biomarker predicts the
response to CRT, vs. coincideswith a beneficial CRT response, and (iii)
sample sizes are generally quite small, except for some larger cohorts.
Moreover, most of the papers discussed are to some extent descrip-
tive and hypothesis-generating, rather than systematically testing or
validating a predefined hypothesis. Also, most molecules are tested
because they are known to be involved in the pathophysiology of HF,
potentially implying some sort of selection bias.
The lack of a universal conclusion on which is the ‘best’ biomarker
to predict the CRT response, is partly to be explained by some limita-
tions, with which we were also confronted when listing the bio-
markers studies. First, all studies used blood sampling as the option of
choice to obtain human material. Related to the site of sampling, al-
though conventional venous puncture is routinely used, CS sampling
might be a favourable option.54 This CS sampling is perfectly feasible
in patients already selected for CRT, but will be hard to perform in
patients who did not undergo eligibility screening. Furthermore,
when sampling the CS, one should also have an idea about the cardiac
output, since the transcoronary gradient is most likely not the only
parameter explaining differences in biomarker levels. Moreover, the
fact that CS sampling would be used is a bit in contradiction with the
fact that a biomarker should be easy to procure. On the other hand,
taking into account the invasiveness and the impact of the implanta-
tion procedure, CS sampling might still be acceptable in this patient
group. Second, an important limitation of this review is related to the
definition of a CRT response which varies significantly in the different
studies in terms of the parameter(s) measured and the time point.
Third, a lot of pilot data are available that did not undergo extensive
validation. Fourth, the often-unclear distinction between ischaemic
and non-ischaemic cardiomyopathy as the underlying pathology
resulting in CRT implantation, may influence the predictive value of
certain biomarkers, as the pathophysiology of non-ischaemic cardio-
myopathy (NICMP) and ischemic cardiomyopathy (ICMP) is largely
different. And last but not least, a careful distinction has to be made
between studies investigating a single, vs. multiple, biomarkers. With
respect to the latter drawback, the MARC study55 nicely showed
one of the problems with biomarker research: several of 16 investi-
gated biomarkers were independently associated with the CRT re-
sponse, but their significance diminished in a multivariate analysis.
Conclusions
Different promising candidate biomarkers have arisen that could po-
tentially do the job, albeit maybe in a ‘signature panel’. However, large














































































































prospective patient cohorts need to be studied and several bio-
markers would need to be investigated simultaneously, in order to
have a reliable head-to-head comparison. Therefore, important chal-
lenges are ahead of us in order to complete the endeavour of finding
the optimal biomarker to predict the response to CRT.
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